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doi:10.1016/j.jmu.2011.03.001Marfan syndrome (MFS) is a rare disease that has a devastating outcome when cardiovascular
complications occur. MFS diagnostic criteria have been revised several times since the causa-
tive mutation was detected. The most specific diagnostic phenotype is cardiovascular manifes-
tation, which also signals the need for close follow-up; MFS patients may ultimately develop
lethal complications during their third or fourth decade of life. An echocardiographer must
be familiar with the cardiovascular presentation of the MFS patient and be aware of specific
measures to be followed if MFS is suspected. Patients should be examined carefully for other
disease symptoms to differentiate MFS from alternative diagnoses.
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Recently, many teenagers were referred to my clinic for
possible Marfan syndrome (MFS) because they had been
diagnosed with mitral valve prolapse (MVP), had thin bodies
and long limbs, and some of them presented with-Chieh Yu, Department of
ics, National Taiwan Univer-
oad, Taipei, Taiwan. E-mail:
C and the Chinese Taipei Societycomplaints of loose joints. In Taiwan, the common social
impression of body image is “the thinner the prettier”;
hence, most teenagers are very thin. In addition, over-
diagnosis of MVP is causing clinicians to more frequently
suspect MFS. The number of teenagers who fulfill the
criteria of being tall, thin, and having MVP are increasingly
referred by schools for MFS screening.
In 1896, Dr. Marfan first described a 5-year-old girl with
long slender digits and other skeletal abnormalities; since
then, understanding about MFS has increased progressively.
We now know its genetic background (FBN1 mutation),
potential pathophysiology [transforming growth factor-beta
dysregulation (TGF-b)], and key manifestations (aorticof Ultrasound in Medicine. Open access under CC BY-NC-ND license.
Fig. 2. A 23-year-old male, 183 cm/64 kg, has sporadic FBN1
mutation. He has pectus carinatum, pes planus, and dural
ectasia. He suffered from recurrent pneumothorax. He has
a typical feature of onion-shaped aortic root.
2 C.-C. Yu, Y.-N. Su, J.-L.Lin, et aldilatation and ectopia lentis). The revised Ghent nosology
2010 [1] contrasted with the 1996 [2] version by simplifying
diagnosis, avoiding criteria that had not been validated,
and eliminating expensive and specialized examinations.
Similar to the previous version, the revised guidelines still
emphasize the importance of dilated aortic root (AR),
ectopia lentis, and the FBN1 mutation. All other minor
manifestations and system involvements, which are
weighted less for an MFS diagnosis, are grouped into
a “systemic features” box. Dural ectasia, a major criterion
in 1996, is now featured only in the Systemic Features box.
The systemic features box also includes skeletal features,
MVP, and other less specific associations. The international
expert panel dedicated themselves to developing a more
practical tool for clinicians to diagnose MFS more easily and
consistently, thereby allowing further discussion or study.
Here, we revisit this rare disease from the perspective of
an echocardiographer. We discuss what is known about this
disease and the focus areas in cases of suspected MFS. We
also consider areas of uncertainty.
1. Aorta
AR dilatation is the most specific MFS finding. The
pattern of dilatation, a so called “onion shape,” is
specific to MFS (Figs. 1 and 2). Several issues should be
considered while performing a cardiac echo in MFS
patients:
a. The AR diameter should be adjusted according to
body surface area (BSA)
Roman et al [3] developed a nomogram of the AR
diameter at the sinus of Valsalva in relation to BSA
according to age; it is currently the most widely
cited reference because it covers the entire spec-
trum of ages. The measured diameter can be
compared with the nomogram, or the Z-score can be
calculated as shown below. A Z-score greater than
or equal to 2 is considered positive for MFS.
 Age: 15 years or less
Mean predicted AR (cm)Z 1.02þ (0.98 BSA)
Standard deviation (SD)Z 0.18 cm
ZZ (measured AR predicted AR)/0.18.Fig. 1. A 30-year-old female, 179 cm/80 kg, has FBN1
mutation and ectopia lentis. Her mother died of acute aortic
dissection when she was young. She has a typical picture of
onion-shaped aortic root. Age: 20e40 years
Mean predicted AR (cm)Z 0.97þ (1.12 BSA)
SDZ 0.24 cm
ZZ (measured AR predicted AR)/0.24.
 Age: greater than 40 years
Mean predicted AR (cm)Z 1.92þ (0.74 BSA)
SDZ 0.37 cm
ZZ (Measured AR predicted AR)/0.37.
b. The appropriate measurement methods should be
determined according to the applied formula
The AR is usually measured by M-mode at the
end-diastolic phase in the parasternal long-axis view
while perpendicular to the long-axis of the aorta;
the interrogation line is placed on the tip of the
aortic valve. The diameter is usually measured from
the upper edge to the upper edge on M-mode;
however, M-mode measurements were found to be
systemically smaller than 2-dimensional (2D)
measurements. Hence, different methods of
measurement may result in different Z-scores. The
new guideline in 2010 suggests accounting for all
differences by using the appropriate formula to
calculate Z-scores. For example, when considering
the formula described in 1.a. above, Roman’s
method should be used to measure the AR; this is
performed on a 2D image, from inner edge to inner
edge, rather than from leading edge to leading
edge.
c. Similar abnormalities should be investigated
Several alternative diagnoses may present with
an echo picture similar to that observed in MFS
patients. Most can be carefully differentiated by
examination of features from other systems. For
example, a bifid uvula is a sign of Loeys-Dietz
syndrome, and translucent/loose skin is a sign of
Ehlers-Danlos syndrome. However, premature aortic
stenosis could potentially develop into secondary AR
dilatation, such as congenital bicuspid aortic valve,
in a young man. Thus, even if a dilated AR is
observed and MFS is suspected, the aortic valve
morphology should be carefully examined to exclude
Fig. 4. A 21-year-old female, 171 cm/64 kg, has FBN1
mutation, sporadic mutation, and has dilatation of aortic sinus
and aortic annulus with moderate-to-severe aortic regurgita-
tion. She then received aortic root grafting and aortic valve
replacement later.
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morphology cannot be confirmed from the trans-
thoracic view, transesophageal echocardiography
should be performed.
d. Asian population cohorts should be used to construct
nomograms
Present data are mainly derived from Western
Caucasian populations; Asian and Taiwanese data
are lacking. The average body shape of a Taiwanese
individual differs from the shape of a Caucasian
individual, partly because of different genetic
backgrounds and partly because of different diet
cultures. The Taiwanese population is generally
thinner and shorter and has a lower body mass index
than the average of the United States. It is unknown
whether Caucasians differ in AR size compared with
Asians with the same BSA and age. Furthermore,
most referred subjects are thinner than their peers;
therefore, their calculated BSAs are relatively
smaller, resulting in smaller estimated AR diame-
ters. Thus, even with the same AR diameter as
others of the same generation and body height, the
decreased BSA decreases the normal AR range in this
type of subject. Thus, the measured AR in these
subjects constitutes the upper border of the normal
range or extends beyond the normal range. Whether
this represents a false-positive diagnosis or a mean-
ingful finding is unknown. Careful follow-up is sug-
gested for these subjects.
e. In addition to the aortic sinus (usually the largest
component of the AR), the sinotubular junction,
aortic annulus, and ascending aorta should be
measured
Although the AR in MFS is typically described as
an onion shape, several variations have been
observed (Fig. 3). Dilatation of the aortic annulus is
associated with the severity of aortic regurgitation
(Fig. 4)
f. Discrepancies between the echo picture and other
imaging facilities should be clarifiedFig. 3. A 49-year-old male, 168 cm/64 kg, has FBN1mutation
and family history of sudden death. He has an atypical picture
of aortic root dilatation of aorta above sinotubular junction,
and the aortic sinus is normal.Communications between doctors about the data
from different imaging facilities should be inter-
preted cautiously. Based on computed tomography
and magnetic resonance imaging images, radiolo-
gists usually report the diameters from one axial
plane, rather than use a 3D workstation. Further-
more, the measurements may be from outer to
outer edge, rather than from inner to inner edge.
Clinicians and surgeons should understand these
inconsistencies, discuss the data with patients, and
determine patient-dependent critical management
strategies.
2. Mitral valve prolapse
Mitral valve involvement is frequently observed in
MFS patients (Figs. 5e7); hence, people with MVP and
marfanoid features are referred to the MFS clinic.
However, attention should be focused on several issues.
a. A correct diagnosis of MVP
Vague diagnostic criteria have increasingly
hampered detailed study of this affliction. The
reported prevalence of MVP ranges widely between
2% and 38%, implying the uncertainty of the diag-
nosis. It is difficult to clearly differentiate MVP from
the normal complex shape of the mitral valve
apparatus. The annulus of the mitral valve is not
a circle but shaped more like a saddle; the anterior
leaflet area is larger than the posterior area, but the
anterior leaflet occupies only one of the three of the
annular circumference. The anterior and posterior
leaflets are each composed of three segments,
named A1eA3 and P1eP3 from medial to lateral. A
prolapse of the medial segment (A1 or P1) would be
missed if no comprehensive survey was performed.
On the contrary, a normal leaflet would be mis-
diagnosed as a prolapse if an apical four-chamber
view was overinterpreted. Hence, if the complexity
of the mitral valve apparatus is not understood, it
is easy to become misled and diagnose MVP using
only one or two 2D views. This issue can also be
Fig. 5. A 16-year-old male has FBN1 mutation and family
history of acute aortic dissection. Prolapse of anterior mitral
leaflet was observed, but no regurgitation was revealed by
color Doppler imaging.
Fig. 7. A 30-year-old female, 179 cm/58 kg, has FBN1
mutation and typical onion-shaped aortic root. She also has
prolapse of anterior and posterior mitral leaflets with mild
mitral regurgitation.
4 C.-C. Yu, Y.-N. Su, J.-L.Lin, et alcountered by using 3D transthoracic echo or trans-
esophageal echo to view the whole mitral valve
structure; new 3D software quantifies the move-
ment of the mitral valve apparatus. The images
could be acquired either by reconstruction or in
real-time 3D zoom mode. The prolapsed valve can
be localized accurately, making it more feasible to
measure between the leaflet segments. Although
color Doppler-based 3D imaging is still limited,
evolving computing compatibility should enhance its
capability within the next few years. The evolution
of these novel tools warrants further study on MVP in
MFS patients, and an increased mechanistic under-
standing of MVP should be anticipated.
b. Coexistence with other pathologies
MVP is often not the only pathology. The preva-
lence of chordae tendineae rupture in prolapsed
valves is higher than that in the normal population
probably because of the underlying tissue pathology
or the stressed hemodynamics on the prolapseFig. 6. A 34-year-old female, 176 cm/58 kg, has ectopia
lentis and FBN1 mutation. She has mild mitral valve prolapse.leaflets. Furthermore, because an eccentric turbu-
lent flow is commonly observed from a prolapsed
mitral leaflet, risk of infection is higher than that in
the normal structure. One retrospective study of
mitral valve surgery in MFS patients revealed that
regurgitation was caused by leaflet prolapse in five
of nine patients and by chordal rupture because of
endocarditis in two patients; annulus dilatation was
observed in all patients [4]. Because coexisting
pathologies can deteriorate mitral leaflet compe-
tence, they should be carefully studied if aggrava-
tions because of regurgitation are observed.
c. Severity of mitral insufficiency
A prolapsed mitral leaflet may not damage the
heart if the open and close functions are main-
tained. Because the regurgitation flow is often
extremely eccentric, the regurgitation severity
often cannot be evaluated by quantitative methods,
such as proximal isovelocity surface area (PISA)
measurements. If no significant aortic regurgitation
coexists, echocardiographers can calculate the
difference between cardiac output (from the left
ventricular outflow tract) and mitral inflow. Clini-
cians should also consider other variables in the
heart, such as left atrium (LA) and left ventricle (LV)
size, systolic and diastolic function, pulmonary vein
flow, and tricuspid regurgitation pressure gradient,
to comprehensively evaluate the impact of mitral
insufficiency.
3. LV and LA function
Myocardial dysfunction in MFS has been observed for
a decade. In the era before tissue Doppler imaging
(TDI), prolonged mitral inflow deceleration time, iso-
volumic relaxation time, and decreased mitral E/A
ratio, which suggested impaired LV relaxation, had all
been reported [5,6]. With the evolution of TDI, diastolic
function impairment and mild LV systolic dysfunction
were revealed. Reduced peak systolic velocities at the
basal septal and lateral myocardial wall, increased end-
systolic volumes, and lower peak early diastolic veloc-
ities at the mitral valve annulus were reported [7]. The
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lateral, septal, inferior, anterior, and posterior mitral
annular regions was also significantly reduced [8]. By
similar methods, atrial functiondreflected by indices
at the reservoir, conduit, and contractile phasesdand
right ventricular functiondreflected by rate of pres-
sure rise (dp/dt), tricuspid annular motion, and peak
TDI systolic velocities at the basal lateral walldwere
both decreased significantly [9,10]. However, because
most of the patients suffered from aortic dilatation or
dissection before developing heart failure, the clinical
impact of these mild but significant changes was
unclear. If the aortic complication could be effectively
postponed by medication or prevented by timely
surgery, the importance of these changes would be
greater and warrant further effort on this issue.
4. Aorta elastance
Autopsies on MFS patient reveal cystic medial
necrosis in the aortic wall. Although the pathophysi-
ology is unclear, it may be associated with uncontrolled
TGF-b, which is normally sequestered by the fibrillin-
composed extracellular matrix. With the FBN1 muta-
tion, the fibrillin structure becomes fragmented and
most TGF-b switches to its active form, causing an
imbalanced dynamic between construction and break-
down in the aortic wall. An animal model has been used
to study the dynamics of the aortic wall; TGF-b-
neutralizing antibody or the angiotensin II Type 1
receptor blocker, losartan, were shown to block TGF-b,
thereby potentially preventing aortic wall breakdown
[11]. Several clinical trials are presently evaluating the
effects of losartan on the aortic pathologic process
compared with those of b-adrenergic blockers [12e14].
Several studies have evaluated aortic characteristics by
traditional or novel echo tools. By using traditional M-
mode tracings, Baumgartner et al [15] demonstrated
decreased aortic distensibility, increased wall stiffness
indices, less of an increase in systolic diameter, and less
of an increase in maximum systolic area. TDI tracings,
the aortic stiffness index, the maximum wall expansion
velocity, and the wall strain were all predictive of
aortic dilatation and dissection [16]. To calculate the
pulsed-wave velocity, Kiotsekoglou et al [17] measured
the blood flow at the aorta near the aortic valve and
immediately afterward in the descending aorta and
demonstrated a significantly higher value in MFS
patients. The aorta is the primary pathological target in
MFS patients; multiple echo parameters were designed
to evaluate minor changes in the aorta, thereby
allowing speculation on the condition of MFS patient
aortas as well as prediction of dilation or dissection
risk. The clinical application of these parameters
requires further study and validation.
5. Pulmonary artery dilatation
Pulmonary artery dilatation was common in MFS
patients; a cutoff value of 23 mm for defining pulmo-
nary artery dilatation was once recommended by De
Backer et al [18]. However, because the criteria lacks
MFS specificity and does not incorporate the rare
complications resulting from pulmonary artery dilata-
tion, it is no longer included in the 2010 revised Ghent
nosology.Conclusion
The incidence of MFS is relatively low (about 1 in 5,000 live
births); however, the rate of cardiovascular complications
is high and the consequences resulting from acute compli-
cations are severe. The clinical and cardiac manifestations
of MFS patients vary widely, even within the same MFS
family. Careful and thorough echocardiography is important
for diagnosis and follow-up in MFS patients. The echocar-
diographer should be aware that not all MFS patients show
full-blown echocardiographic images. The echocardiog-
rapher should also be familiar with each MFS echo finding,
that is, the LA and LV function should be examined in
addition to the AR and mitral valve, and the aortic stiffness
index should be acquired and recorded. The clinical roles of
these novel echocardiographic indices are not well vali-
dated; however, the more information that is collected
from the patient echocardiography examination, the better
the patient aorta condition will be understood, enabling
clinicians and the patients to devise the most effective
management strategy.References
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